The present invention relates to a novel Toxoplasma gondii GRA8-derived recombinant peptide, and a pharmaceutical composition and functional food for preventing or treating cancer, which includes the same as an active ingredient. The Toxoplasma gondii GRA8-derived recombinant peptide according to the present invention is a novel recombinant peptide in which a specific mitochondrial targeting sequence and an ATP5A1/SIRT3 sequence of GRA8 are conjugated to an acidity-triggered rational membrane (ATRAM), and has considerably improved efficacy in which an inhibitory concentration 50 (IC50) is improved up to 200-fold (in vitro) or 500-fold (in vivo), compared with a conventional GRA8-derived peptide (rGRA8). In addition, since the peptide treatment shows a notably distinct therapeutic effect in mouse models with cancer, the peptide may be effectively used in a pharmaceutical composition or functional food for preventing or treating cancer.

The present invention relates to a novel Toxoplasma gondii GRA8-derived recombinant peptide, and a pharmaceutical composition and functional food for preventing or treating cancer, which includes the same as an active ingredient. The Toxoplasma gondii GRA8-derived recombinant peptide according to the present invention is a novel recombinant peptide in which a specific mitochondrial targeting sequence and an ATP5A1/SIRT3 sequence of GRA8 are conjugated to an acidity-triggered rational membrane (ATRAM), and has considerably improved efficacy in which an inhibitory concentration 50 (IC50) is improved up to 200-fold (in vitro) or 500-fold (in vivo), compared with a conventional GRA8-derived peptide (rGRA8). In addition, since the peptide treatment shows a notably distinct therapeutic effect in mouse models with cancer, the peptide may be effectively used in a pharmaceutical composition or functional food for preventing or treating cancer.

A new use of a cyclo histidine-proline (Cyclo His-Pro, CHP) is disclosed. A composition including cyclo histidine-proline (CHP) as an active ingredient has an excellent protective effect to protect kidney and liver cells from damage and/or toxicity induced by various causes. The composition is useful and effective in protecting kidney and/or liver cells/tissues and in treating a subject with kidney and/or liver diseases and/or damages.

Methods and systems for reducing acrylamide concentration in heat-processed products, and products produced by such methods and systems are provided. The baked products may be sprayed with a riboflavin solution and then irradiated with a UV light source to initiate monomer reactions of acrylamide and reduce the concentration of the acrylamide in the baked product. In addition, riboflavin may be dissolved in heat-processed products, followed by irradiation of the riboflavin-containing heat-processed products with a UV light source to initiate monomer reactions of acrylamide and reduce the concentration of the acrylamide in the baked product.

Methods of screening cancerous cells for nutritional weaknesses and methods of treating cancer nutritionally are disclosed. Certain cancers depend on being supplied with one or more nutrients that are non-essential for normal cells. In particular, the invention relates to methods of treating cancer by identifying nutritional weaknesses of cancer cells and using nutritional therapy to suppress cancer by putting a subject on a diet that deprives cancerous cells of a nutrient needed for cancer proliferation and growth. Nutritional therapy can be used to enhance the effectiveness of current cancer treatments.

Methods of screening cancerous cells for nutritional weaknesses and methods of treating cancer nutritionally are disclosed. Certain cancers depend on being supplied with one or more nutrients that are non-essential for normal cells. In particular, the invention relates to methods of treating cancer by identifying nutritional weaknesses of cancer cells and using nutritional therapy to suppress cancer by putting a subject on a diet that deprives cancerous cells of a nutrient needed for cancer proliferation and growth. Nutritional therapy can be used to enhance the effectiveness of current cancer treatments.

A microbial fermentation composition is prepared through after extracting and enzymolyzing selected Edible and medicinal fungi Agaricus blazei, Lentinus edodes, Flammulina velutipes and ginseng of reinforcing vital energy, adding trace elements selenium, zinc and molybdenum, and fermenting and transforming by probiotics. It is demonstrated through experiments of in vitro inhibition of HepGII cells (a liver cancer cell) and Hela cells (a cervical cancer cell) that the fermentation composition formed by probiotic fermentation has significant inhibitory effect on the proliferation of tumor cells. Compared with the non-fermented composition, the fermentation composition has a significantly enhanced inhibitory effect on experimental tumor cells and the difference is significant. The inhibitory effect of the fermentation composition on experimental tumor cells increases with the increase of the concentration.

A microbial fermentation composition is prepared through after extracting and enzymolyzing selected Edible and medicinal fungi Agaricus blazei, Lentinus edodes, Flammulina velutipes and ginseng of reinforcing vital energy, adding trace elements selenium, zinc and molybdenum, and fermenting and transforming by probiotics. It is demonstrated through experiments of in vitro inhibition of HepGII cells (a liver cancer cell) and Hela cells (a cervical cancer cell) that the fermentation composition formed by probiotic fermentation has significant inhibitory effect on the proliferation of tumor cells. Compared with the non-fermented composition, the fermentation composition has a significantly enhanced inhibitory effect on experimental tumor cells and the difference is significant. The inhibitory effect of the fermentation composition on experimental tumor cells increases with the increase of the concentration.

A method for treating an immune disease caused by a Th1/Th2 imbalance in favor of a Th2 shift in a subject including administering a composition comprising Lactobacillus plantarum CJLP133 strain KCTC 11403BP to the subject in need thereof.

A method for treating an immune disease caused by a Th1/Th2 imbalance in favor of a Th2 shift in a subject including administering a composition comprising Lactobacillus plantarum CJLP133 strain KCTC 11403BP to the subject in need thereof.